News

New Alzheimer’s target
Enlarge image

ScienceBelgium

New Alzheimer’s target

04.12.2012 - Scientists from VIB and KU Leuven have discovered a new target that could lay the foundations for a new approach to treat Alzheimer’s disease.

The research team, headed by Bart de Strooper from VIB, found that β-arrestin 2 blocks the plaque-form enzyme γ-secretase through interaction with the G protein–coupled receptors GPR3 and β2 -adrenergic receptor (Nature Medicine). Furthermore, they demonstrated that β-arrestin 2 was overexpressed in two independent cohorts of Alzheimer patients. Overexpression of the protein led to an increase in sticky amyloid-β (Aβ) peptides, called Aβ40 and Aβ42, which form the amyloid plaques that are associated with neurodegeneration. In contrast, genetic silencing of Arrb2, which encodes β-arrestin 2, reduced generation of Aβ in cell cultures and in knock-out mice for the Alzheimer regulator. The effect was mediated by direct binding to the Aph-1a subunit of the γ-secretase complex, which enzymatically generates the sticky Aβ peptides. Thus the scientists believe that inhibitors of β-arrestin 2 could block the generation of Aβ40 and Aβ42, in early stages of Alzheimer’s when no symptoms have yet emerged.

Currently there is no cure for the neurodegenerative disease. Many candidate drugs that target the γ-secretase complex fail because they also target proteins essential to life. The discovery from Leuven could form a target for a treatment against Alzheimer’s disease with fewer side effects and that suppresses the very first symptoms of the disease. β-arrestin 2 inhibition could be beneficial in prevention of the adverse side effects currently associated with γ-secretase inhibition. This study thus provides a previously unexplored avenue for the development of a treatment that can act at a very early stage of Alzheimer’s disease.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/new-alzheimers-target.html

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Berlin (GER)

XIV. BIONNALE 2016

Aachen

Biomedica 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • NOVACYT (F)1.63 EUR17.27%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • BAYER (D)84.42 EUR-5.72%
  • ALMIRALL (E)13.37 EUR-5.51%
  • MOLOGEN (D)3.20 EUR-5.04%

TOP

  • GALAPAGOS (B)51.25 EUR26.5%
  • GENMAB (DK)1205.00 DKK24.2%
  • NICOX (F)10.90 EUR23.9%

FLOP

  • BIOCARTIS GROUP NV (B)8.00 EUR-25.9%
  • BIONOR PHARMA (N)0.68 NOK-25.3%
  • MOBERG PHARMA (S)38.70 SEK-24.9%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.90 SEK1921.0%
  • NICOX (F)10.90 EUR492.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.90 SEK-87.6%
  • BB BIOTECH (D)43.88 EUR-84.9%
  • EVOCUTIS (UK)0.05 GBP-79.2%

No liability assumed, Date: 24.05.2016